Skip to main content

In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299.

Publication ,  Journal Article
Ho, L; Aytac, U; Stephens, LC; Ohnuma, K; Mills, GB; McKee, KS; Neumann, C; LaPushin, R; Cabanillas, F; Abbruzzese, JL; Morimoto, C; Dang, NH
Published in: Clin Cancer Res
July 2001

CD26 is a M(r) 110,000 surface glycoprotein with diverse functional properties, including having a potentially significant role in tumor development, and antibodies to CD26 mediate pleomorphic cellular functions. In this report, we show that binding of soluble anti-CD26 monoclonal Ab 1F7 inhibits the growth of the human CD30+ anaplastic large cell T-cell lymphoma cell line Karpas 299 in both in vitro and in vivo experiments. In vitro experiments show that 1F7 induces cell cycle arrest at the G1-S checkpoint, associated with enhanced p21 expression that is dependent on de novo protein synthesis. Furthermore, experiments with a severe combined immunodeficient mouse tumor model demonstrate that 1F7 treatment significantly enhances survival of tumor-bearing mice by inhibiting tumor formation. Our data therefore suggest that anti-CD26 treatment may have potential clinical use for CD26+ hematological malignancies.

Duke Scholars

Published In

Clin Cancer Res

ISSN

1078-0432

Publication Date

July 2001

Volume

7

Issue

7

Start / End Page

2031 / 2040

Location

United States

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Tumor Cells, Cultured
  • Survival Rate
  • S Phase
  • Proteins
  • Oncology & Carcinogenesis
  • Neoplasm Transplantation
  • Mice, SCID
  • Mice
  • Lymphoma, Large-Cell, Anaplastic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ho, L., Aytac, U., Stephens, L. C., Ohnuma, K., Mills, G. B., McKee, K. S., … Dang, N. H. (2001). In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res, 7(7), 2031–2040.
Ho, L., U. Aytac, L. C. Stephens, K. Ohnuma, G. B. Mills, K. S. McKee, C. Neumann, et al. “In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299.Clin Cancer Res 7, no. 7 (July 2001): 2031–40.
Ho L, Aytac U, Stephens LC, Ohnuma K, Mills GB, McKee KS, et al. In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res. 2001 Jul;7(7):2031–40.
Ho L, Aytac U, Stephens LC, Ohnuma K, Mills GB, McKee KS, Neumann C, LaPushin R, Cabanillas F, Abbruzzese JL, Morimoto C, Dang NH. In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res. 2001 Jul;7(7):2031–2040.

Published In

Clin Cancer Res

ISSN

1078-0432

Publication Date

July 2001

Volume

7

Issue

7

Start / End Page

2031 / 2040

Location

United States

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Tumor Cells, Cultured
  • Survival Rate
  • S Phase
  • Proteins
  • Oncology & Carcinogenesis
  • Neoplasm Transplantation
  • Mice, SCID
  • Mice
  • Lymphoma, Large-Cell, Anaplastic